- Home
- / Myovant Sciences
Myovant Sciences
Revenue
$231 M
FY, 2022
Myovant Sciences Summary
Company Summary
- Overview
- Myovant Sciences is a biopharmaceutical company that focuses on women’s health and prostate cancer. It is engaged in the development of treatments for women suffering from uterine fibroids, endometriosis, and infertility as well as for men suffering from prostate cancer. The company offers ORGOVYX and MYFEMBREE medicines.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2016
- HQ
- Brisbane, CA, US | view all locations
- Website
- https://www.myovant.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Matthew Lang, Chief Administrative and Legal Officer and Corporate Secretary
Uneek Mehra, Chief Financial and Business Officer
Lauren Merendino, Chief Commercial Officer
LocationsView all
2 locations detected
Brisbane, CA HQ
United States
2000 Sierra Point Parkway, 9th Floor
Basel, BS
Switzerland
Viaduktstrasse 8
Myovant Sciences Financials
Summary Financials
- Revenue (Q3, 2023)
- $100.2M
- Net income (Q3, 2023)
- ($57.6M)
- Cash (Q3, 2023)
- $250.6M
- EBIT (Q3, 2023)
- ($51.9M)